IN VITRO DIAGNOSTICS CENTER AT FDA URGED
This article was originally published in The Gray Sheet
IN VITRO DIAGNOSTICS CENTER AT FDA URGED by the In-Vitro Diagnostics Manufacturers Coalition (IMC) in a position paper released at the Utah International Medical Device Congress held Aug. 18-19 in Salt Lake City. Arguing that IVDs "are mistakenly classified as medical devices," IMC maintains that the products "should be removed from the [Center for Devices and Radiological Health] and placed into a new regulatory center."
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.